Early relapses, onset of progression, and late outcome in multiple sclerosis
- PMID: 23407713
- DOI: 10.1001/jamaneurol.2013.599
Early relapses, onset of progression, and late outcome in multiple sclerosis
Abstract
Objectives: To investigate the relationship among attacks in the first 2 years (early relapses), secondary progression (SP), and late disability in multiple sclerosis (MS).
Design: Cohort study with follow-up of 28 years.
Setting: Referral MS center.
Patients: Patients (N=730) with relapsing-remitting MS diagnosed according to Poser criteria, from the database of the London Multiple Sclerosis Clinic, London, Ontario, Canada.
Main outcome measure: Long-term evolution of patients with high (≥ 3 attacks) and early (within the first 2 years of the disease) frequency of relapses. In the total SP population and in patients grouped by numbers of early relapses, we assessed the predictive effect of latency to progression (time to SP) on times to attain cane requirement (Disability Status Scale score of 6 [DSS 6]) and bedridden status (DSS 8).
Results: Among the group with frequent early relapses (n=158), outcomes were variable. Although 103 (65.2%) experienced rapid conversion to SP MS (median duration, 5 years) and rapidly attained DSS 6 and DSS 8 scores (7 and 17 years, respectively), the remainder (n=55) did not enter the SP phase, despite adverse early relapse features. Among the total SP population, longer latency to progression was associated with lower probability of attaining DSS 6 (odds ratio, 0.76 [95% CI, 0.69-0.84] and 0.44 [95% CI, 0.37-0.52] for 5- and 15-year latency, respectively) and longer times to severe disability. The same association between time to onset of SP and late outcomes was observed even in patients matched by number of early attacks. However, duration of the relapsing-remitting phase did not influence the times from SP onset to DSS levels.
Conclusions: Our results indicate dissociation between early inflammatory attacks and onset of the SP phase and further question the validity of relapse frequency as a surrogate marker for late disability. Among the group with frequent early relapses, we observed a large variability of outcomes, ranging from one extreme to the opposite.
Similar articles
-
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9. Brain. 2010. PMID: 20534650 Free PMC article.
-
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.Neurology. 2006 Sep 26;67(6):944-53. doi: 10.1212/01.wnl.0000237994.95410.ce. Neurology. 2006. PMID: 17000959 Clinical Trial.
-
The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.Brain. 2006 Mar;129(Pt 3):584-94. doi: 10.1093/brain/awh721. Epub 2006 Jan 9. Brain. 2006. PMID: 16401620
-
Management of worsening multiple sclerosis with mitoxantrone: a review.Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
-
The incomplete nature of multiple sclerosis relapse resolution.J Neurol Sci. 2007 May 15;256 Suppl 1:S14-8. doi: 10.1016/j.jns.2007.01.062. Epub 2007 Mar 2. J Neurol Sci. 2007. PMID: 17337274 Review.
Cited by
-
Cerebellar and/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review.Front Neurol. 2022 Apr 29;13:874388. doi: 10.3389/fneur.2022.874388. eCollection 2022. Front Neurol. 2022. PMID: 35572921 Free PMC article. Review.
-
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course.Lancet Reg Health Eur. 2024 Aug 22;44:100977. doi: 10.1016/j.lanepe.2024.100977. eCollection 2024 Sep. Lancet Reg Health Eur. 2024. PMID: 39444703 Free PMC article. Review.
-
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials.Front Neurol. 2020 Jun 17;11:489. doi: 10.3389/fneur.2020.00489. eCollection 2020. Front Neurol. 2020. PMID: 32625161 Free PMC article.
-
["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].Nervenarzt. 2015 Dec;86(12):1528-37. doi: 10.1007/s00115-015-4439-x. Nervenarzt. 2015. PMID: 26556094 Review. German.
-
Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis.Mult Scler. 2023 Apr;29(4-5):606-614. doi: 10.1177/13524585231152433. Epub 2023 Feb 8. Mult Scler. 2023. PMID: 36755463 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources